Allelic Discrimination, Polymerase Chain Reaction (PCR)
Activated protein C (APC), a serine protease, limits clot formation by proteolytic inactivation of factor Va (and VIIIa). Resistance of FVa to degradation by APC is associated with an increased risk of venous thromboemobolism (VTE). This resistance is caused by a specific point mutation in the gene coding for the coagulation factor V (F5 c.1601G>A; rs6025; g.169549811C>T; NC_000001.11; NM_000130.4; previously designated c.1691G>A) which results in the replacement of amino acid Arg 534 (CGA) by Gln (CAA) (F5 R534Q; previously designated R506Q R506Q Leiden). This amino acid substitution prevents inactivation of factor Va by APC. Other genetic as well as environmental factors may also influence the risk of thrombosis. Genetic counseling may be indicated.
Interpretive report provided.
2 - 14 days
- Activated Protein C Resistance by DNA Analysis
- Factor 5 Leiden
- Factor 5 Leiden Mutation Detection
- Factor V Leiden by DNA Analysis
- F5 Gene Mutation Detection
- Factor V Mutation Study
- Factor V Q506 Leiden
- Factor V Leiden Mutation
- FACTOR V LEIDEN
Collect blood in a lavender top tube. Refrigerate and send intact blood within 48 hours of collection.
To reduce inappropriate thrombophilia testing in the inpatient population this test has been removed from the inpatient test catalog. If there is a specific clinical need for this test on an inpatient please contact the Coagulation Laboratory.
By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws and the ordering clinician has authorization from the patient permitting MLabs to report the test results to the ordering clinician. Test includes pathologist interpretation of results billed as a separate additional charge. This test is not available without interpretation.